Skip to main content
. 2015 Jul 8;126(9):1078–1085. doi: 10.1182/blood-2015-03-630897

Figure 3.

Figure 3

Mean annualized bleeding rates (ABRs) in subjects who received prophylactic treatment with BAX 855 are depicted by target joint status at screening. There were 101 subjects in the PPAS, including 69 subjects with no target joints at screening and 32 subjects with target joints at screening. Median ABR values are also presented.